论文部分内容阅读
采用随机、单盲、安慰剂及正常对照的方法，观察了４８例慢性支气管炎（慢支）急性发作期患者痰及血中６－酮－前列腺素Ｆ１ａ（６－ｋｅｔｏ－ＰＧＦ１ａ）、血栓素Ｂ２（ＴＸＢ２）含量的变化以及它们与疾量，痰干／湿比，肺活量实测值占预计值百分比（ＶＣ％），１秒用力肺活量占用力肺活量百分比（ＦＥＶ１％）的相关性。并观察了消炎痛对它们的影响。结果表明：慢支患者痰及血中６－ｋｅｔｏ－ＰＧＦ１ｕ及ＴＸＢ２均高于正常对照组（Ｐ＜０．０１）。痰及血中６—ｋｅｔｏ－ＰＧＦ１ａ和ＴＸＢ２与痰量和疾干／湿比里正相关（Ｐ＜０．０１）；与ＶＣ％和ＦＥＶ１％呈负相关（Ｐ＜０．０５，Ｐ＜０．０１）。与安慰剂组相比消炎痛雾化吸入可明显降低慢支患者的痰量，痰粘度和血沉（Ｐ＜０．０１）；明显提高ＶＣ％和ＦＥＶ１％（Ｐ值分别小于０．０５，Ｐ＜０．０１）；明显缩短病程（Ｐ＜０．０５）。
A randomized, single-blind, placebo-controlled and placebo-controlled study was conducted in 48 sputum and 6-keto-prostaglandin F1a (6-keto-PGF1a), thromboxane B2 (TXB2) content and their correlation with disease volume, sputum wet / dry ratio, measured value of vital capacity (VC%) and forced vital capacity of one second (FEV1%). And observed the impact of indomethacin on them. The results showed that 6-keto-PGF1u and TXB2 in sputum and blood of patients with chronic bronchitis were higher than those in normal control group (P <0.01). Phlegm and blood 6-keto-PGF1a and TXB2 were positively correlated with sputum volume and dry / wet ratio (P <0.01), negatively correlated with VC% and FEV1% (P <0.05, P <0 .01). Compared with the placebo group, inhalation of indomethacin could significantly reduce sputum volume, sputum viscosity and erythrocyte sedimentation rate in patients with chronic bronchitis (P <0.01), significantly increase VC% and FEV1% (P values were less than 0.05, P <0.01). The course of disease was significantly shortened (P <0.05).